1. Academic Validation
  2. Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells

Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells

  • Oncotarget. 2016 Oct 4;7(40):66087-66099. doi: 10.18632/oncotarget.11807.
Shuju Zhang 1 Jiaming Zhang 1 Zhiyuan Deng 2 Huadie Liu 1 Wei Mao 1 Fang Jiang 1 Zanxian Xia 1 Jia-Da Li 1
Affiliations

Affiliations

  • 1 The State Key Laboratory of Medical Genetics and School of Life Sciences, Central South University, Changsha, Hunan 410078, China.
  • 2 Xiangya Stomatological Hospital, Central South University, Changsha, Hunan 410078, China.
Abstract

The Anticancer small molecule MLN4924, a NEDD8-activating Enzyme (NAE) inhibitor, triggers cell-cycle arrest, Apoptosis, and senescence in Cancer cells. In this study, we demonstrate that MLN4924 suppresses osteosarcoma cell proliferation by inducing G2/M cell cycle arrest and Apoptosis. Our results indicate that MLN4924 stabilizes the retinoid orphan nuclear receptor alpha (RORα) by decreasing its ubiquitination. RNA interference of RORα attenuates the anti-proliferative effect of MLN4924 in U2OS osteosarcoma cells. MLN4924 up-regulates the expression of p21 and Bmal1, two transcriptional targets of RORα. However, p21 plays a minimal role in the anti-proliferative effect of MLN4924 in U2OS osteosarcoma cells. In contrast, Bmal1 suppression by siRNA attenuates the anti-proliferative effect of MLN4924 in U2OS osteosarcoma cells, indicating that the MLN4924-mediated cell growth inhibition is mediated by Bmal1. These results show MLN4924 to be a promising therapeutic agent for the treatment of osteosarcoma and suggest that MLN4924-induced tumor growth inhibition is mediated by the circadian clock components RORα and Bmal1.

Keywords

Bmal1; MLN4924; RORα; neddylation; osteosarcoma.

Figures
Products